Photosensitizer
Phase 3Small molecule
Photosensitizer is one of 6 small molecule programs targeting Bile Duct Cancer. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Bile Duct Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerApproved
Ixempra
RR-Pharm
Approved
Photofrin
PPinnacle Biologics Inc.
Approved
Photosensitizer
UUniversity of Leipzig
Phase 3
Tecentriq
RochePreclinical
Fotivda
AAVEO Pharmaceuticals, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiac1 trial
Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer
Unknown status·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 3·NCT02628665·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Photosensitizer. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Leipzig